Skip to main content

Advertisement

Table 3 Cox proportional hazards regression of all patients for progression-free survival and overall survival

From: Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study

Variables Progression-free survival Overall survival
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Age > 65 1.11 (0.763 to 1.604) 0.594 1.11 (0.653 to 1.894) 0.694
Sex (male) 0.94 (0.628 to 1.422) 0.786 1.38 (0.787 to 2.407) 0.263
Smoking 1.08 (0.605 to 1.936) 0.791 1.68 (0.820 to 3.450) 0.156
EGFR mutation
 L858R Reference   Reference  
 Del 19 0.97 (0.664 to 1.413) 0.867 0.99 (0.558 to 1.772) 0.985
 Uncommon mutation 2.40 (0.851 to 6.753) 0.098 3.75 (1.401 to 10.027) 0.009
 Complex mutations 3.12 (1.111 to 8.777) 0.038 2.20 (0.645 to 7.523) 0.208
Initial brain metastases number ≥ 3 1.17 (0.796 to 1.726) 0.422 2.43 (1.277 to 4.629) 0.007
Other metastases location
 Lung 1.33 (0.921 to 1.918) 0.129 1.56 (0.925 to 2.642) 0.095
 Bone 1.42 (0.963 to 2.090) 0.077 1.70 (0.948 to 3.045) 0.075
 Liver 1.58 (0.981 to 2.558) 0.060 2.03 (1.071 to 3.831) 0.041
 Pleura 1.33 (0.880 to 2.019) 0.175 1.42 (0.808 to 2.495) 0.223
 Other location 1.84 (1.112 to 3.038) 0.018 1.59 (0.818 to 3.085) 0.172
M1c (definition by AJCC 8th edition) 1.63 (0.812 to 3.269) 0.169 1.55 (0.555 to 4.348) 0.402
Radiotherapy to brain metastases 0.78 (0.523 to 1.175) 0.239 1.19 (0.690 to 2.064) 0.527
Brain tumor excision 0.75 (0.344 to 1.630) 0.466 0.40 (0.097 to 1.645) 0.204
PD location
 Intracranial only Reference   Reference  
 Extracranial only 1.10 (0.724 to 1.683) 0.646 1.71 (0.903 to 3.259) 0.100
 Both 1.03 (0.537 to 1.978) 0.927 0.90 (0.322 to 2.541) 0.849
TKI
 Gefitinib Reference   Reference  
 Erlotinib 0.88 (0.584 to 1.324) 0.539 1.14 (0.627 to 2.065) 0.670
 Afatinib 1.03 (0.620 to 1715) 0.907 1.39 (0.642 to 3.001) 0.404